Vázquez Carballo, CristinaGuerrero Hue, MelaniaGarcía Caballero, Cristina G.Rayego Mateos, SandraOpazo Ríos, LucasMorgado Pascual, José LuisHerencia Bellido, CarmenVallejo Mudarra, MercedesCortegano Jimeno, María IsabelGaspar, María LuisaDe Andrés, BelénEgido, JesúsMoreno González De Eiris, Elena2023-06-172023-06-172021-01-11Vázquez Carballo, C., Guerrero Hue, M., García Caballero, C. G. et al. «Toll-Like Receptors in Acute Kidney Injury». International Journal of Molecular Sciences, vol. 22, n.o 2, enero de 2021, p. 816. DOI.org (Crossref), https://doi.org/10.3390/ijms22020816.1422-006710.3390/ijms22020816https://hdl.handle.net/20.500.14352/7350The authors work has been supported by grants from Instituto de Salud Carlos III (ISCIII, FIS-FEDER PI17/00130, PI17/01495, PI20/00375, PI20/00487), Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM) and Cardiovascular (CIBERCV), Spanish Ministry of Science and Innovation (RTI2018-099114-B-100, RTI2018-098788-B-100, DTS19/00093, RYC-2017-22369), and Spanish Societies of Cardiology (SEC), Nephrology (SEN) and Atherosclerosis (SEA). The “PFIS” and “Sara Borrell” training program of the ISCIII supported the salary of MGH (FI18/00310), SR-M (CD19/00021) and CH-B (CP16/00017). Córdoba University supported the salary of C.G.C.Acute kidney injury (AKI) is an important health problem, affecting 13.3 million individuals/year. It is associated with increased mortality, mainly in low- and middle-income countries, where renal replacement therapy is limited. Moreover, survivors show adverse long-term outcomes, including increased risk of developing recurrent AKI bouts, cardiovascular events, and chronic kidney disease. However, there are no specific treatments to decrease the adverse consequences of AKI. Epidemiological and preclinical studies show the pathological role of inflammation in AKI, not only at the acute phase but also in the progression to chronic kidney disease. Toll-like receptors (TLRs) are key regulators of the inflammatory response and have been associated to many cellular processes activated during AKI. For that reason, a number of anti-inflammatory agents targeting TLRs have been analyzed in preclinical studies to decrease renal damage during AKI. In this review, we updated recent knowledge about the role of TLRs, mainly TLR4, in the initiation and development of AKI as well as novel compounds targeting these molecules to diminish kidney injury associated to this pathological condition.engAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/journal articlehttps://doi.org/10.3390/ijms22020816https://www.mdpi.com/1422-0067/22/2/816https://www.mdpi.com/journal/ijmsopen access616.61Toll-like receptorsInflammationAcute kidney injuryDrugsTherapyMedicinaNefrología y urología32 Ciencias Médicas